Difference between revisions of "Team:NCTU Formosa"

Line 30: Line 30:
 
          
 
          
 
}
 
}
−
        .div3-1{
+
.div3-1{
 
         background:#fff;
 
         background:#fff;
−
         width:28%;
+
         width:28%;
 
         position:absolute;
 
         position:absolute;
 
         left:8%;
 
         left:8%;
−
top:0vh;
+
height:100%;
 +
top:0vh;
 +
        margin-left:0;  
 
}
 
}
 
         .div3-2{
 
         .div3-2{
 
         background:#fff;
 
         background:#fff;
 
         width:28%;
 
         width:28%;
−
position:absolute;
+
height:100%;
 +
position:absolute;
 
         left:36%;
 
         left:36%;
−
top:0vh;
+
top:0vh;
 +
        margin-left:0;  
 
}
 
}
 
         .div3-3{
 
         .div3-3{
 
         background:#fff;
 
         background:#fff;
 
         width:28%;
 
         width:28%;
−
position:absolute;
+
height:100%;
 +
position:absolute;
 
         left:64%;
 
         left:64%;
−
top:0vh;
+
top:0vh;
 +
        margin-left:0;  
 
}
 
}
 
         .div4{
 
         .div4{

Revision as of 18:10, 16 September 2015

1
The only thing we can detect is everything.

Who are we

NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO devoted to developing detection technology by utilizing antibodies. In 2015, We cooperated with iGEM with Synthetic Biology to develop a brand new detection platform.

What's new

APOllO E.Cotector:
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen-antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.

What do we care

In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more patients can afford it. Therefore, more patients can be prescribed and treated, lowering the mortality rate of cancer.